Hümeyra ÇANAKÇI, Cenk Fatih ÇANAKÇI, Ebru SAĞLAM, Ayşe TORAMAN, Metin İNGEÇ, Engin SEBİN

Endocan and Interleukin-6 Levels in Individuals with polycystic ovary syndrome and periodontal inflammation: A prospective cross-sectional stud

Aim: Periodontitis and polycystic ovary syndrome (PCOS) are relationship to both chronic low-grade inflammation and systemic inflammation. In spite of common risk factors, the link between periodontitis and PCOS has not yet been clear. The aims of the current cross-sectional study are to determine serum and saliva endocan and interleukin-6(IL-6) levels, and to evaluate the correlation between these two biomarkers in women with periodontitis and PCOS. Materials and Methods: 87 individuals divided into four groups; PCOS with periodontitis (PCOSP), PCOS but periodontally healthy (PCOSPH), systemically healthy with periodontitis (SHP) and control group. Demographics, periodontal parameters, serum and saliva endocan and IL-6 values were evaluated. Results: Serum endocan values in all the study groups were significantly greater than those in the control group. Saliva endocan values in PCOSP group were greater than those in the control group. Serum IL-6 values in both the PCOSP and SHP groups were significantly greater than those in the control group. Saliva IL-6 values in both periodontitis groups were significantly greater than those in the control groups. There were significant positive correlations between the serum and saliva endocan and saliva IL-6 values (p

PDF

___

1. Ozcaka O, Ceyhan BO, Akcali A, et al. Is there an interaction between polycystic ovary syndrome and gingival inflammation? J Periodontol 2012;83:1529- 37.
2. Cekici A, Kantarci A, Hasturk H, et al. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000 2014;64:57-80.
3. D'Aiuto F, Sabbah W, Netuveli G, et al. Association of the metabolic syndrome with severe periodontitis in a large U.S. population-based survey. J Clin Endocrinol Metab 2008;93:3989-94.
4. Tonetti MS, Van Dyke TE. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitisand Systemic Diseases. J Periodontol 2013;84:24-9.
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
6. Sabuncu T, Vural H, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:407-13.
7. Spritzer PM, Lecke SB, Satler F, et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015;149:R219-27.
8. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-64.
9. Rocha SF, Schiller M, Jing D, et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res 2014;115:581-90.
10. Yang J, Yang Q, Yu S, et al. Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep 2015;3:279-83.
11. Scherpereel A, Gentina T, Grigoriu B, et al. Overexpression of endocan induces tumor formation. Cancer Res 2003;63:6084-9.
12. Bilir B, Ekiz Bilir B, Yilmaz I, et al. Association of apelin, endoglin and endocan with diabetic peripheral neuropathy in type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2016;20:892-8.
13. Wang XS, Yang W, Luo T, et al. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015;19:124-7.
14. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behcet disease. J Am Acad Dermatol 2014;70:291-6.
15. Icli A, Cure E, Cure MC, et al. Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology 2016;67:749-55.
16. Voiosu T, Balanescu P, Bengus A, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab 2014;60:505-10.
17. Girasole G, Jilka RL, Passeri G, et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrowderived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992;89:883-91.
18. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitaryadrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690-4.
19. Festa A, D'Agostino R, Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42- 7.
20. Ozcaka O, Buduneli N, Ceyhan BO, et al. Is interleukin-17 involved in the interaction between polycystic ovary syndrome and gingival inflammation? J Periodontol 2013;84:1827-37.
21. Deepti, Tewari S, Narula SC, et al. Effect of nonsurgical periodontal therapy along with myo-inositol on high-sensitivity c-reactive protein and insulin resistance in women with polycystic ovary syndrome and chronic periodontitis: a randomized controlled trial. J Periodontol 2017;88:999-1011.
22. Rahiminejad ME, Moaddab A, Zaryoun H, et al. Comparison of prevalence of periodontal disease in women with polycystic ovary syndrome and healthy controls. Dent Res J (Isfahan) 2015;12:507-12.
23. Dursun E, Akalin FA, Guncu GN, et al. Periodontal disease in polycystic ovary syndrome. Fertil Steril 2011;95:320-3.
24. Bicer M, Guler A, Unal Kocabas G, et al. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res 2017;42:145-53.
25. Cakir E, Ozbek M, Ozkaya E, et al. Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients. J Endocrinol Invest 2011;34:e178-82.
26. Silness J, Loe H. Periodontal disease in pregnancy. ii. correlation between oral hygiene and periodontal condtion. Acta Odontol Scand 1964;22:121-35.
27. Loe H, Silness J. Periodontal Disease in pregnancy. I. prevalence and severity. Acta Odontol Scand 1963;21:533-51.
28. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
29. Page RC, Eke PI. Case definitions for use in populationbased surveillance of periodontitis. J Periodontol 2007;78 (Suppl 7S):1387-99.
30. Bechard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099-106.
31. Turer CC, Durmus D, Balli U, et al. Effect of non-surgical periodontal treatment on gingival crevicular fluid and serum endocan, vascular endothelial growth factor-a and tumor necrosis factor alpha levels. J Periodontol 2017:88:493-501.
32. Pietruska M, Pietruski JK, Stokowska W, et al. Interleukin 6 and its soluble receptor in periodontitis. Arch Immunol Ther Exp (Warsz) 1998;46:305-9.
33. Murata T, Miyazaki H, Senpuku H, et al. Periodontitis and serum interleukin-6 levels in the elderly. Jpn J Infect Dis 2001;54:69-71.
34. Tarkun I, Cetinarslan B, Turemen E, et al. Association between circulating tumor necrosis factor-alpha, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome. Metab Syndr Relat Disord 2006;4:122-8.
35. Olszanecka-Glinianowicz M, Banas M, Zahorska-Markiewicz B, et al. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol 2007;133:197-202.
36. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011;95:1048-58 e1041-2.
37. Prakasam S, Srinivasan M. Evaluation of salivary biomarker profiles following non-surgical management of chronic periodontitis. Oral Dis 2014;20:171-7.
38. Ebersole JL, Schuster JL, Stevens J, et al. Patterns of salivary analytes provide diagnostic capacity for distinguishing chronic adult periodontitis from health. J Clin Immunol 2013;33:271-9.
39. Rathnayake N, Akerman S, Klinge B, et al. Salivary biomarkers of oral health: a cross-sectional study. J Clin Periodontol 2013;40:140-7.
40. Teles RP, Likhari V, Socransky SS, et al. Salivary cytokine levels in subjects with chronic periodontitis and in periodontally healthy individuals: a crosssectional study. J Periodontal Res 2009;44:411-7.